JP2023524996A5 - - Google Patents

Info

Publication number
JP2023524996A5
JP2023524996A5 JP2022567342A JP2022567342A JP2023524996A5 JP 2023524996 A5 JP2023524996 A5 JP 2023524996A5 JP 2022567342 A JP2022567342 A JP 2022567342A JP 2022567342 A JP2022567342 A JP 2022567342A JP 2023524996 A5 JP2023524996 A5 JP 2023524996A5
Authority
JP
Japan
Prior art keywords
independently
alkyl
symptoms
pharmaceutically acceptable
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022567342A
Other languages
English (en)
Japanese (ja)
Other versions
JP7705884B2 (ja
JP2023524996A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/030540 external-priority patent/WO2021226002A1/en
Publication of JP2023524996A publication Critical patent/JP2023524996A/ja
Publication of JP2023524996A5 publication Critical patent/JP2023524996A5/ja
Application granted granted Critical
Publication of JP7705884B2 publication Critical patent/JP7705884B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022567342A 2020-05-05 2021-05-04 ガレクチン-3の低分子阻害剤 Active JP7705884B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063020041P 2020-05-05 2020-05-05
US63/020,041 2020-05-05
PCT/US2021/030540 WO2021226002A1 (en) 2020-05-05 2021-05-04 Small molecule inhibitors of galectin-3

Publications (3)

Publication Number Publication Date
JP2023524996A JP2023524996A (ja) 2023-06-14
JP2023524996A5 true JP2023524996A5 (cg-RX-API-DMAC10.html) 2024-05-16
JP7705884B2 JP7705884B2 (ja) 2025-07-10

Family

ID=76076509

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567342A Active JP7705884B2 (ja) 2020-05-05 2021-05-04 ガレクチン-3の低分子阻害剤

Country Status (6)

Country Link
US (1) US12275720B2 (cg-RX-API-DMAC10.html)
EP (1) EP4146646A1 (cg-RX-API-DMAC10.html)
JP (1) JP7705884B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230006547A (cg-RX-API-DMAC10.html)
CN (1) CN115551855A (cg-RX-API-DMAC10.html)
WO (1) WO2021226002A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2631509A (en) * 2023-07-04 2025-01-08 Univ Liverpool Compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
ES2652488T3 (es) 2009-04-28 2018-02-02 Galecto Biotech Ab Nuevos inhibidores de galactósidos de galectinas
KR102231732B1 (ko) 2012-10-10 2021-03-23 갈렉틴 테라퓨틱스, 인크. 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물
IN2015DN02573A (cg-RX-API-DMAC10.html) 2012-10-31 2015-09-11 Galecto Biotech Ab
CA2970062C (en) 2015-01-30 2023-02-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
CA3000924A1 (en) 2015-11-09 2017-05-18 Galecto Biotech Ab Novel galactoside inhibitors of galectins
KR102626669B1 (ko) 2017-05-12 2024-01-17 갈랙틴 사이언시즈, 엘엘씨 질환의 예방 및 치료를 위한 화합물 및 이의 용도
CA3062649A1 (en) * 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the treatment of systemic insulin resistance disorders and the use thereof
EP3807290B1 (en) 2018-06-15 2022-03-30 Bristol-Myers Squibb Company Tetrahydropyran-based thiodisaccharide mimics as galectin-3 inhibitors

Similar Documents

Publication Publication Date Title
JP2022527395A5 (cg-RX-API-DMAC10.html)
JP2022527075A5 (cg-RX-API-DMAC10.html)
JP2021508686A5 (cg-RX-API-DMAC10.html)
JP2023531709A5 (cg-RX-API-DMAC10.html)
JP2019526582A5 (cg-RX-API-DMAC10.html)
JP2020510664A5 (cg-RX-API-DMAC10.html)
JP2021527102A5 (cg-RX-API-DMAC10.html)
JP6824952B2 (ja) mIDH1阻害剤としての2−アリール−および2−アリールアルキル−ベンズイミダゾール
EP3793995B1 (en) Matrix metalloproteinase (mmp) inhibitors and methods of use thereof
JP2016517432A5 (cg-RX-API-DMAC10.html)
JP2015509098A5 (cg-RX-API-DMAC10.html)
JP2021502387A5 (cg-RX-API-DMAC10.html)
JP2007508238A5 (cg-RX-API-DMAC10.html)
JP2023533203A5 (cg-RX-API-DMAC10.html)
JP2022545158A5 (cg-RX-API-DMAC10.html)
US20120027682A1 (en) Pyrazine Derivatives for Optical Imaging and Therapy
JP2023531495A5 (cg-RX-API-DMAC10.html)
JP2022545159A5 (cg-RX-API-DMAC10.html)
JP2006513221A5 (cg-RX-API-DMAC10.html)
JP2021505541A5 (cg-RX-API-DMAC10.html)
TWI555744B (zh) Novel EP4 agonists
JP2010540649A5 (cg-RX-API-DMAC10.html)
WO2007002637B1 (en) N-linked heterocyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
JP2008516989A (ja) 組成物及び抗腫瘍剤としてのその使用
JP2023527396A5 (cg-RX-API-DMAC10.html)